Increased monitoring capacity of deadly prion diseases
Posted: 19 April 2024 A state-of-the-art service based at The Florey is increasing its capacity to protect the public from the fatal brain condition Creutzfeldt-Jakob disease (CJD). The rare neurodegenerative illness, caused by misfolded proteins called prions in…
Melbourne home to one-of-a-kind electron microscope
Posted: 19 April 2024 A suite of three electron microscopes, including one of the highest resolution microscopes in the world, now calls Monash home, helping scientists push the frontiers in materials science to solve complex worldwide challenges. The…
IDT Secures contract with Sanofi Australia
Posted: 19 April 2024 IDT Australia Limited (ASX: IDT) (IDT Australia) is pleased to announce that it has entered into a Master Service Agreement with Sanofi, an innovative global healthcare company, to support the preclinical formulation development and…
Receive a discount on research and clinical trial training programs
Posted: 17 April 2024 In the lead up to the EOFY, BioMelbourne Network partner PRAXIS Australia are offering you and your team their most generous offer yet on their expert training solutions. If you enrol now, you can receive 24%…
First Patient Enrolled Major e-health Respiratory Management Clinical Study
Posted: 16 April 2024 Leading digital health company Adherium Limited (ASX:ADR) is pleased to announce the first patient has been enrolled in a newly cemented research partnership between US Intermountain Health and CareCentra using Hailie® sensors to monitor…
Adherium Unveils New FDA-Cleared Smartinhaler® Compatible with Airsupra® and Breztri® Inhalation Devices
Posted: 16 April 2024 Adherium Limited ( “Adherium” or “the Company”; ASX:ADR), a global leader in digital health technologies addressing chronic respiratory diseases, is pleased to announce that its innovative Hailie® Smartinhaler® has received clearance from the U.S.…
TLX101-CDx (Pixclara™) Granted FDA Fast Track Designation
Posted: 16 April 2024 Telix today announces that the United States (U.S.) Food and Drug Administration (FDA) has granted Fast Track designation1 for the Company’s investigational glioma imaging product, TLX101-CDx (Pixclara™2, 18F-floretyrosine or 18F-FET). The granted Fast Track designation is for…
Seaport Therapeutics receives US$100 million in funding to maximise Monash invention
Posted: 16 April 2024 Seaport Therapeutics, a clinical-stage biopharmaceutical company based around a unique drug delivery platform originally developed by Monash University researchers, today announced the closing of a $100 million oversubscribed Series A financing round. The round…
Protein could help detect delayed concussion recovery
Posted: 16 April 2024 Melbourne researchers have discovered a blood protein that could help detect which children will experience ongoing concussion symptoms more than two weeks after an injury. The research, led by Murdoch Children’s Research Institute (MCRI)…
Victorian research finds hearing aids boost brain function
Posted: 16 April 2024 Hearing aid users experience benefits to their brain function according to new results from Victorian medical researchers. Thanks to the Victorian Government’s Victorian Medical Research Acceleration Fund (VMRAF) and Sonova AG, the Evaluation of…
Radiation therapy triggering the immune system
Posted: 15 April 2024 Peter Mac researcher Dr Benjamin Blyth is studying how radiation therapy can trigger an immune response in the body the way a vaccine does. Understanding this could lead to new treatments that optimise the use of…
New international study finds triple-negative breast cancer patients could avoid chemotherapy
Posted: 15 April 2024 Peter Mac researchers are part of a major international study that has found patients with early-stage triple-negative breast cancer (TNBC) and high levels of immune cells could be spared from intensive chemotherapy regimens. TNBC…
